Navigation Links
ImaginAb Expands Scientific Advisory Board
Date:11/25/2013

LOS ANGELES, Nov. 25, 2013 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it has added three new members to its Scientific Advisory Board (SAB). ImaginAb welcomes Dr. Karl Dane Wittrup, Dr. Peter Senter and Dr. Michael Zalutsky, each of whom contributes a history of scientific leadership in a discipline that is fundamental to future applications of ImaginAb's technology.

"The addition of Dr. Wittrup, Dr. Senter and Dr. Zalutsky to the ImaginAb advisory team is an exciting opportunity for ImaginAb to better understand how to position molecular imaging technology to therapeutic areas of growing commercial importance to the company," commented Dr. Anna Wu, ImaginAb's Chief Scientist. "Their expertise in protein engineering, ADC technology and radioimmunoconjugates complements the molecular imaging and mAb platform technology leadership present in our SAB."

Dr. Karl Dane Wittrup, C.P. Dubbs Professor of Chemical Engineering at the Massachusetts Institute of Technology (MIT) and Assoc. Director of the Koch Institute for Integrative Cancer Research has joined ImaginAb's SAB. Dr. Wittrup, a highly recognized thought leader in the field of yeast display, brings tremendous vision and expertise in the field of protein engineering.

Dr. Peter Senter is a pioneer in the field of antibody-drug conjugates (ADCs) and brings tremendous perspective in a field of importance to ImaginAb because of the company's growing focus on building companion diagnostic imaging products for ADC therapeutics.

Dr. Michael Zalutsky is a Professor, Department of Radiology, Radiation Oncology and Biomedical Engineering and Jonathan Spicehandler M.D. Professor of Neuro-Oncology Research at Duke University. The addition of Dr. Zalutsky marks the beginning of a more formal foray into radioimmunoconjugates for therapeutic purposes, including the potential of using alpha-emitting isotopes in conjunction with ImaginAb's minibody platform.

The addition of Drs. Wittrup, Senter and Zalutsky also marks the formal retirement from ImaginAb's SAB of Dr. Steven Larson, the Donna and Benjamin M. Rosen Chair in Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Dan Shochat, formerly Vice President of Development at KaloBios Pharmaceuticals Inc. has joined the management of ImaginAb on a part-time basis as Vice President of Manufacturing and also steps down from ImaginAb's SAB.

Drs. Wittrup, Senter and Zalutsky join founding ImaginAb SAB members Dr. Sanjiv "Sam" Gambhir, Virginia and D.K. Ludwig Professor in Cancer Research, Director Stanford Molecular Imaging Program and Dr. James D. Marks, Professor, Departments of Anesthesia and Pharmaceutical Chemistry, UCSF.

"We welcome these new members to our SAB, but also warmly thank Dr. Larson and Dr. Shochat for their outstanding service to our SAB during the start-up phase of ImaginAb – their advice and continuous challenge of our scientific and commercial assumptions was invaluable," noted Dr. Christian Behrenbruch, CEO of ImaginAb. "We'd particularly like to thank Dr. Larson who has been a driving force in the development of our PSMA minibody technology, currently under clinical investigation at MSKCC."

About ImaginAb

ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging.  The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare. For more information, visit www.imaginab.com.


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Edison expands international biotechnology presence with launch of full coverage of Athersys
2. VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark
3. TransCelerate BioPharma Inc. Launches Second Year Initiatives, Expands Membership and Achieves Milestones for Original Projects
4. ACell Expands Indiana Manufacturing Facility to Support Growth
5. BSMA Expands Advisory Board to Advance BIOTECH SUPPLY CHAIN
6. Annai Systems Expands Access to GTFuse for Rapid and Cost-effective Use of Sequencing Data
7. Digiscribe Expands Document Scanning Services
8. MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer
9. PTC Therapeutics Expands Management Team
10. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
11. Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... York, New York (PRWEB) , ... ... ... Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the Human ... and immunotherapies for infectious diseases and cancer. , The Human Vaccines ...
(Date:2/10/2016)... Feb. 10, 2016  Matchbook, Inc., a company ... growing biotech companies, announced today the appointment of ... Advisor. Jim brings nearly 25 years of experience ... having spent nearly two decades in executive level ... Procurement at Genzyme and, most recently headed global ...
(Date:2/10/2016)... , ... February 10, 2016 , ... LATHAM, NEW YORK... ... the SPIE Photonics West conference in San Francisco’s Moscone Center from February ... the same venue. , These latest InGaAs PIN diode standard packages feature a ...
(Date:2/10/2016)... Boston, MA (PRWEB) , ... February 10, 2016 ... ... system is now available on Microsoft Azure. On Azure, Arvados provides capabilities for ... “We saw clear demand for Microsoft Azure from major institutions collecting and analyzing ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
Breaking Biology News(10 mins):